Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Lurasidone Hydrochloride"" wg kryterium: Temat


Tytuł :
Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR.
Autorzy :
Restelli U; Center for Health Economics, Social and Health Care Management, University Carlo Cattaneo-LIUC, Corso Matteotti, 22, 21053, Castellanza, VA, Italy. .; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. .
García-Goñi M; Department of Applied and Structural Economics and History, Faculty of Economics and Business, Universidad Complutense de Madrid, Madrid, Spain.
Lew-Starowicz M; Department of Psychiatry, Centre of Postgraduate Medical Education, Warsaw, Poland.; Institute of Psychiatry and Neurology, Warsaw, Poland.
Mierzejewski P; Department of Pharmacology, Institute of Psychiatry and Neurology, Warsaw, Poland.
Silvola S; Center for Health Economics, Social and Health Care Management, University Carlo Cattaneo-LIUC, Corso Matteotti, 22, 21053, Castellanza, VA, Italy.
Mayoral-van Son J; University Hospital Virgen del Rocio, University of Sevilla, CIBERSAM, Seville, Spain.
Croce D; Center for Health Economics, Social and Health Care Management, University Carlo Cattaneo-LIUC, Corso Matteotti, 22, 21053, Castellanza, VA, Italy.
Rocca P; Department of Neuroscience, University of Turin, Turin, Italy.
Crespo-Facorro B; University Hospital Virgen del Rocio, University of Sevilla, CIBERSAM, Seville, Spain.
Pokaż więcej
Źródło :
Clinical drug investigation [Clin Drug Investig] 2020 Sep; Vol. 40 (9), pp. 861-871.
Typ publikacji :
Journal Article
MeSH Terms :
Antipsychotic Agents/*therapeutic use
Lurasidone Hydrochloride/*therapeutic use
Quetiapine Fumarate/*therapeutic use
Schizophrenia/*drug therapy
Adult ; Antipsychotic Agents/economics ; Chronic Disease ; Cost-Benefit Analysis ; Female ; Hospitalization/economics ; Humans ; Italy ; Lurasidone Hydrochloride/economics ; Middle Aged ; Models, Economic ; Quetiapine Fumarate/economics ; Recurrence ; Spain ; State Medicine
Czasopismo naukowe
Tytuł :
Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
Autorzy :
Arango C; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón. IiSGM, School of Medicine, Universidad Complutense, CIBERSAM. Av. Séneca 2, 28040, Madrid, Spain.
Ng-Mak D; Sunovion Pharmaceuticals Inc, 84 Waterford Drive, Marlborough, MA, 01752, USA. .
Finn E; IQVIA, 210 Pentonville Rd, London, N1 9JY, UK.
Byrne A; IQVIA, 210 Pentonville Rd, London, N1 9JY, UK.
Loebel A; Sunovion Pharmaceuticals Inc, One Bridge Plaza North, Suite 510, Fort Lee, NJ, 07024, USA.
Pokaż więcej
Źródło :
European child & adolescent psychiatry [Eur Child Adolesc Psychiatry] 2020 Sep; Vol. 29 (9), pp. 1195-1205. Date of Electronic Publication: 2019 Nov 22.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Antipsychotic Agents/*therapeutic use
Lurasidone Hydrochloride/*therapeutic use
Schizophrenia/*drug therapy
Adolescent ; Antipsychotic Agents/pharmacology ; Female ; Humans ; Lurasidone Hydrochloride/pharmacology ; Male ; Network Meta-Analysis
Czasopismo naukowe
Tytuł :
Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study.
Autorzy :
Higuchi T; Japan Depression Center, Tokyo, Japan.
Ishigooka J; Institute of CNS Pharmacology, Tokyo, Japan.
Iyo M; Department of Psychiatry, National University Corporation Chiba University, Graduate School of Medicine, Chiba, Japan.
Hagi K; Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan.
Pokaż więcej
Źródło :
Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists [Asia Pac Psychiatry] 2020 Mar; Vol. 12 (1), pp. e12377. Date of Electronic Publication: 2019 Dec 13.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms :
Antipsychotic Agents/*pharmacology
Lurasidone Hydrochloride/*pharmacology
Schizophrenia/*drug therapy
Adult ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/adverse effects ; Female ; Humans ; Japan ; Lurasidone Hydrochloride/administration & dosage ; Lurasidone Hydrochloride/adverse effects ; Malaysia ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Republic of Korea ; Taiwan
Czasopismo naukowe
Tytuł :
Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies.
Autorzy :
Jazuli I; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India.
Annu; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India.
Nabi B; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India.
Moolakkadath T; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India.
Alam T; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India.
Baboota S; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India.
Ali J; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India. Electronic address: .
Pokaż więcej
Źródło :
Journal of pharmaceutical sciences [J Pharm Sci] 2019 Sep; Vol. 108 (9), pp. 3082-3090. Date of Electronic Publication: 2019 May 08.
Typ publikacji :
Journal Article
MeSH Terms :
Antipsychotic Agents/*pharmacokinetics
Brain/*metabolism
Drug Carriers/*chemistry
Lipids/*chemistry
Lurasidone Hydrochloride/*pharmacokinetics
Nanoparticles/*chemistry
Administration, Intranasal ; Animals ; Antipsychotic Agents/administration & dosage ; Chemistry, Pharmaceutical ; Drug Design ; Humans ; Lurasidone Hydrochloride/administration & dosage ; Male ; Microscopy, Electron, Scanning ; Microscopy, Electron, Transmission ; Models, Chemical ; Nanoparticles/ultrastructure ; Particle Size ; Rats ; Rats, Wistar ; Schizophrenia/drug therapy ; Solubility ; Surface Properties
Czasopismo naukowe
Tytuł :
Lurasidone inhibits NMDA receptor antagonist-induced functional abnormality of thalamocortical glutamatergic transmission via 5-HT 7 receptor blockade.
Autorzy :
Okada M; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu, Japan.
Fukuyama K; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu, Japan.
Ueda Y; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu, Japan.
Pokaż więcej
Źródło :
British journal of pharmacology [Br J Pharmacol] 2019 Oct; Vol. 176 (20), pp. 4002-4018. Date of Electronic Publication: 2019 Sep 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antipsychotic Agents/*pharmacology
Dizocilpine Maleate/*antagonists & inhibitors
Lurasidone Hydrochloride/*pharmacology
Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors
Receptors, Serotonin/*metabolism
Serotonin Antagonists/*pharmacology
Animals ; Antipsychotic Agents/administration & dosage ; Dizocilpine Maleate/pharmacology ; Glutamic Acid/drug effects ; Glutamic Acid/metabolism ; Lurasidone Hydrochloride/administration & dosage ; Male ; Mediodorsal Thalamic Nucleus/drug effects ; Perfusion ; Rats ; Rats, Sprague-Dawley ; Receptors, N-Methyl-D-Aspartate/metabolism ; Serotonin Antagonists/administration & dosage ; Synaptic Transmission/drug effects ; Thalamus/drug effects ; Thalamus/metabolism
Czasopismo naukowe
Tytuł :
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
Autorzy :
Corponi F; Department of Biomedical and Neuromotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123, Bologna, Italy.
Fabbri C; Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom.
Bitter I; Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
Montgomery S; Imperial College School of Medicine, London, UK.
Vieta E; Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
Kasper S; Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Pallanti S; Institute of Neuroscience, Florence, Italy; Department of Psychiatry and Behavioral Science, Stanford University Medical Center, Stanford, CA, USA.
Serretti A; Department of Biomedical and Neuromotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123, Bologna, Italy. Electronic address: .
Pokaż więcej
Źródło :
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology [Eur Neuropsychopharmacol] 2019 Sep; Vol. 29 (9), pp. 971-985. Date of Electronic Publication: 2019 Jun 27.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antipsychotic Agents/*therapeutic use
Heterocyclic Compounds, 4 or More Rings/*therapeutic use
Lurasidone Hydrochloride/*therapeutic use
Piperazines/*therapeutic use
Quinolones/*therapeutic use
Thiophenes/*therapeutic use
Animals ; Antipsychotic Agents/adverse effects ; Heterocyclic Compounds, 4 or More Rings/adverse effects ; Humans ; Lurasidone Hydrochloride/adverse effects ; Mental Disorders/drug therapy ; Piperazines/adverse effects ; Quinolones/adverse effects ; Thiophenes/adverse effects
Czasopismo naukowe
Tytuł :
Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.
Autorzy :
Higuchi T; Japan Depression Center, Tokyo, Japan.
Iyo M; Department of Psychiatry, National University Corporation Chiba University, Chiba, Japan.
Kwon JS; Department of Psychiatry, College of Medicine, Seoul National University, Seoul, South Korea.
Chou YH; Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.; Institute of Biophotonics, National Yang-Ming University, Taipei, Taiwan.
Chen HK; Department of General Psychiatry, Yu-Li Hospital, Hualien, Taiwan.
Chen JY; Yu-Li Veterans Hospital, Hualien, Taiwan.
Chen TT; National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.
Huang SY; Tri-service General Hospital, Taipei, Taiwan.
Lee JS; Yongin Mental Hospital, Seoul, South Korea.
Saeki Y; Gannosu hospital, Fukuoka, Japan.
Tanaka H; Tanaka Hospital, Gunma, Japan.
Wang TS; Department of Psychiatry, Taipei Tzu Chi Hospital, Taipei, Taiwan.
Wu BJ; Department of General Psychiatry, Yu-Li Hospital, Hualien, Taiwan.
Katoh T; Department of Internal Medicine, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Ishigouoka J; Institute of CNS Pharmacology, Tokyo, Japan.
Pokaż więcej
Źródło :
Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists [Asia Pac Psychiatry] 2019 Sep; Vol. 11 (3), pp. e12354. Date of Electronic Publication: 2019 Mar 25.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Antipsychotic Agents/*therapeutic use
Lurasidone Hydrochloride/*therapeutic use
Risperidone/*therapeutic use
Schizophrenia/*drug therapy
Adolescent ; Adult ; Aged ; Double-Blind Method ; Female ; Humans ; Lurasidone Hydrochloride/adverse effects ; Male ; Middle Aged ; Risperidone/adverse effects ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Lurasidone-Induced Mania.
Autorzy :
Ward HB; Department of Psychiatry, Brigham & Women's Hospital, 60 Fenwood Rd, Boston, MA 02115. .; Department of Psychiatry, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Almeida M; Department of Psychiatry, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Pokaż więcej
Źródło :
The primary care companion for CNS disorders [Prim Care Companion CNS Disord] 2019 Jul 11; Vol. 21 (4). Date of Electronic Publication: 2019 Jul 11.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antipsychotic Agents/*adverse effects
Bipolar Disorder/*chemically induced
Lurasidone Hydrochloride/*adverse effects
Adult ; Antipsychotic Agents/therapeutic use ; Bipolar Disorder/drug therapy ; Female ; Humans ; Lurasidone Hydrochloride/therapeutic use ; Olanzapine/therapeutic use
Czasopismo naukowe
Tytuł :
Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
Autorzy :
Ng-Mak D; Sunovion Pharmaceuticals, 84 Waterford Dr, Marlborough, MA 01752. Email: .
Messali A
Huang A
Wang L
Loebel A
Pokaż więcej
Źródło :
The American journal of managed care [Am J Manag Care] 2019 Jul; Vol. 25 (14 Suppl), pp. S279-S286.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antipsychotic Agents/*adverse effects
Aripiprazole/*adverse effects
Lurasidone Hydrochloride/*adverse effects
Olanzapine/*adverse effects
Quetiapine Fumarate/*adverse effects
Risperidone/*adverse effects
Schizophrenia/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antipsychotic Agents/therapeutic use ; Aripiprazole/therapeutic use ; Female ; Hospitalization/statistics & numerical data ; Humans ; Lurasidone Hydrochloride/therapeutic use ; Male ; Middle Aged ; Olanzapine/therapeutic use ; Quetiapine Fumarate/therapeutic use ; Risk Factors ; Risperidone/therapeutic use
Czasopismo naukowe
Tytuł :
Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Autorzy :
Demyttenaere K; Department of Neurosciences, Research Group Psychiatry, Department of Psychiatry, Faculty of Medicine, University Psychiatric Center KU Leuven and University of Leuven, Campus Gasthuisberg, Herestraat 49, 3000, Louvain, Belgium. .
Detraux J; Department of Neurosciences, Research Group Psychiatry, KU Leuven, University Psychiatric Centre, 3070, Kortenberg, Belgium.
Racagni G; Department of Pharmacological Sciences, Università degli Studi di Milano, Milan, Italy.
Vansteelandt K; Department of Neurosciences, Research Group Psychiatry, KU Leuven, University Psychiatric Centre, 3070, Kortenberg, Belgium.
Pokaż więcej
Źródło :
CNS drugs [CNS Drugs] 2019 Jun; Vol. 33 (6), pp. 549-566.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Akathisia, Drug-Induced/*etiology
Antipsychotic Agents/*adverse effects
Lurasidone Hydrochloride/*adverse effects
Piperazines/*adverse effects
Akathisia, Drug-Induced/epidemiology ; Antipsychotic Agents/therapeutic use ; Bipolar Disorder/drug therapy ; Depressive Disorder, Major/drug therapy ; Humans ; Lurasidone Hydrochloride/therapeutic use ; Piperazines/therapeutic use ; Randomized Controlled Trials as Topic ; Schizophrenia/drug therapy ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
Exanthematous Rash With Lurasidone in an Elderly Woman With Schizoaffective Disorder.
Autorzy :
Hafeez ZH; Department of Psychiatry, Kaiser Permanente, Santa Rosa, California, USA.; Department of Psychiatry, Touro University, Vallejo, California, USA.
Pokaż więcej
Źródło :
The primary care companion for CNS disorders [Prim Care Companion CNS Disord] 2019 Mar 28; Vol. 21 (2). Date of Electronic Publication: 2019 Mar 28.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antipsychotic Agents/*adverse effects
Exanthema/*chemically induced
Lurasidone Hydrochloride/*adverse effects
Psychotic Disorders/*drug therapy
Aged ; Antipsychotic Agents/therapeutic use ; Exanthema/drug therapy ; Exanthema/pathology ; Female ; Humans ; Lurasidone Hydrochloride/therapeutic use
Czasopismo naukowe
Tytuł :
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.
Autorzy :
Mattingly GW; Washington University School of Medicine, St. Louis, MO, USA.
Haddad PM; Hamad Medical Corporation, Doha, Qatar.; Clinical Professor of Psychiatry, Qatar University, Doha, Qatar.; Honorary Professor of Psychiatry, University of Manchester, Manchester, UK.; Honorary Consultant Psychiatrist, GMMH NHS Foundation Trust, Manchester, UK.
Tocco M; Sunovion Pharmaceuticals Inc., Fort Lee, NJ, 84 Waterford Dr, Marlborough, MA, 01752, USA. .
Xu J; Sunovion Pharmaceuticals Inc., Fort Lee, NJ, 84 Waterford Dr, Marlborough, MA, 01752, USA.
Phillips D; Sunovion Pharmaceuticals Inc., Fort Lee, NJ, 84 Waterford Dr, Marlborough, MA, 01752, USA.
Pikalov A; Sunovion Pharmaceuticals Inc., Fort Lee, NJ, 84 Waterford Dr, Marlborough, MA, 01752, USA.
Loebel A; Sunovion Pharmaceuticals Inc., Fort Lee, NJ, 84 Waterford Dr, Marlborough, MA, 01752, USA.
Pokaż więcej
Źródło :
BMC psychiatry [BMC Psychiatry] 2020 May 05; Vol. 20 (1), pp. 199. Date of Electronic Publication: 2020 May 05.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Lurasidone Hydrochloride/*administration & dosage
Lurasidone Hydrochloride/*therapeutic use
Metabolic Syndrome/*chemically induced
Risperidone/*administration & dosage
Risperidone/*therapeutic use
Schizophrenia/*complications
Schizophrenia/*drug therapy
Adult ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/therapeutic use ; Double-Blind Method ; Female ; Humans ; Male ; Metabolic Syndrome/complications ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Comparison of Lurasidone and Quetiapine in Critically Ill Patients.
Autorzy :
Kleinman RA; 1 Department of Psychiatry and Behavioral Health Sciences, Stanford University, Palo Alto, CA, USA.
Pokaż więcej
Źródło :
Journal of intensive care medicine [J Intensive Care Med] 2019 Feb; Vol. 34 (2), pp. 171. Date of Electronic Publication: 2018 Jul 19.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antipsychotic Agents*
Lurasidone Hydrochloride*
Critical Illness ; Humans ; Quetiapine Fumarate
Opinia redakcyjna
Tytuł :
Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
Autorzy :
Broder MS; Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA.
Greene M; Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, USA. Electronic address: .
Yan T; Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA.
Chang E; Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA.
Hartry A; Lundbeck, Deerfield, IL, USA.
Yermilov I; Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA.
Pokaż więcej
Źródło :
Clinical therapeutics [Clin Ther] 2019 Feb; Vol. 41 (2), pp. 221-232. Date of Electronic Publication: 2019 Jan 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antipsychotic Agents/*therapeutic use
Depressive Disorder, Major/*drug therapy
Lurasidone Hydrochloride/*therapeutic use
Quetiapine Fumarate/*therapeutic use
Quinolones/*therapeutic use
Thiophenes/*therapeutic use
Adolescent ; Adult ; Aged ; Antipsychotic Agents/economics ; Depressive Disorder, Major/economics ; Emergency Service, Hospital/economics ; Emergency Service, Hospital/statistics & numerical data ; Female ; Health Care Costs ; Hospitalization/economics ; Hospitalization/statistics & numerical data ; Humans ; Lurasidone Hydrochloride/economics ; Male ; Medicaid/economics ; Medicare/economics ; Medication Adherence/statistics & numerical data ; Middle Aged ; Patient Acceptance of Health Care ; Quetiapine Fumarate/economics ; Quinolones/economics ; Thiophenes/economics ; United States ; Young Adult
Czasopismo naukowe
Tytuł :
Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features).
Autorzy :
Targum SD; Bracket Global, LLC, Boston, Massachusetts, USA.
Pendergrass JC; Bracket Global, LLC, Boston, Massachusetts, USA.
Lee S; Bracket Global, LLC, Boston, Massachusetts, USA.
Loebel A; Sunovion Pharmaceuticals, Fort Lee, New Jersey, USA.; Sunovion Pharmaceuticals, Marlborough, Massachusetts, USA.
Pokaż więcej
Źródło :
International journal of methods in psychiatric research [Int J Methods Psychiatr Res] 2018 Dec; Vol. 27 (4), pp. e1729. Date of Electronic Publication: 2018 Jun 26.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Severity of Illness Index*
Antipsychotic Agents/*pharmacology
Bipolar Disorder/*drug therapy
Depressive Disorder, Major/*drug therapy
Interview, Psychological/*standards
Lurasidone Hydrochloride/*pharmacology
Outcome Assessment, Health Care/*standards
Psychiatric Status Rating Scales/*standards
Adult ; Antipsychotic Agents/administration & dosage ; Double-Blind Method ; Humans ; Lurasidone Hydrochloride/administration & dosage ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis.
Autorzy :
Ostacher M; a Department of Psychiatry and Behavioral Sciences , Stanford University School of Medicine , Palo Alto , CA , USA.
Ng-Mak D; b Global HEOR, Sunovion Pharmaceuticals Inc , Marlborough , MA , USA.
Patel P; c Health Outcomes, Kantar Health , New York , NY , USA.
Ntais D; d Real-World Evidence Solutions, QuintilesIMS , London , UK.
Schlueter M; e Health Economics & Outcomes Research , Real-World Evidence Solutions, QuintilesIMS , London , UK.
Loebel A; f Sunovion Pharmaceuticals Inc , Fort Lee , NJ , USA.
Pokaż więcej
Źródło :
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry [World J Biol Psychiatry] 2018 Dec; Vol. 19 (8), pp. 586-601. Date of Electronic Publication: 2017 Mar 07.
Typ publikacji :
Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Network Meta-Analysis*
Antipsychotic Agents/*pharmacology
Bipolar Disorder/*drug therapy
Lurasidone Hydrochloride/*pharmacology
Antipsychotic Agents/adverse effects ; Humans ; Lurasidone Hydrochloride/adverse effects
Czasopismo naukowe
Tytuł :
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Autorzy :
Leucht S; Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich (Leucht, Siafis); Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Leucht, Patel); Department of Global Public Health, Karolinska Institutet, Stockholm (Orsini); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Crippa); Department of Psychiatry, University of Illinois at Chicago, and John Hopkins School of Medicine, Baltimore (Davis).
Crippa A; Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich (Leucht, Siafis); Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Leucht, Patel); Department of Global Public Health, Karolinska Institutet, Stockholm (Orsini); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Crippa); Department of Psychiatry, University of Illinois at Chicago, and John Hopkins School of Medicine, Baltimore (Davis).
Siafis S; Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich (Leucht, Siafis); Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Leucht, Patel); Department of Global Public Health, Karolinska Institutet, Stockholm (Orsini); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Crippa); Department of Psychiatry, University of Illinois at Chicago, and John Hopkins School of Medicine, Baltimore (Davis).
Patel MX; Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich (Leucht, Siafis); Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Leucht, Patel); Department of Global Public Health, Karolinska Institutet, Stockholm (Orsini); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Crippa); Department of Psychiatry, University of Illinois at Chicago, and John Hopkins School of Medicine, Baltimore (Davis).
Orsini N; Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich (Leucht, Siafis); Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Leucht, Patel); Department of Global Public Health, Karolinska Institutet, Stockholm (Orsini); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Crippa); Department of Psychiatry, University of Illinois at Chicago, and John Hopkins School of Medicine, Baltimore (Davis).
Davis JM; Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich (Leucht, Siafis); Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Leucht, Patel); Department of Global Public Health, Karolinska Institutet, Stockholm (Orsini); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Crippa); Department of Psychiatry, University of Illinois at Chicago, and John Hopkins School of Medicine, Baltimore (Davis).
Pokaż więcej
Źródło :
The American journal of psychiatry [Am J Psychiatry] 2020 Apr 01; Vol. 177 (4), pp. 342-353. Date of Electronic Publication: 2019 Dec 16.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Dose-Response Relationship, Drug*
Schizophrenic Psychology*
Antipsychotic Agents/*administration & dosage
Schizophrenia/*drug therapy
Acute Disease ; Administration, Oral ; Aripiprazole/administration & dosage ; Clozapine/administration & dosage ; Delayed-Action Preparations ; Haloperidol/administration & dosage ; Humans ; Imidazoles/administration & dosage ; Indoles/administration & dosage ; Isoxazoles/administration & dosage ; Lurasidone Hydrochloride/administration & dosage ; Olanzapine/administration & dosage ; Paliperidone Palmitate/administration & dosage ; Piperazines/administration & dosage ; Piperidines/administration & dosage ; Quetiapine Fumarate/administration & dosage ; Quinolones/administration & dosage ; Risperidone/administration & dosage ; Schizophrenia/physiopathology ; Thiazoles/administration & dosage ; Thiophenes/administration & dosage
Czasopismo naukowe
Tytuł :
C-reactive protein and response to lurasidone in patients with bipolar depression.
Autorzy :
Raison CL; School of Human Ecology, University of Wisconsin-Madison, 1300 Linden Drive, Madison, WI 53706, USA; Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison, 6001 Research Park Blvd, Madison, WI 53719, USA. Electronic address: .
Pikalov A; Sunovion Pharmaceuticals Inc., 1 Bridge Plaza North, Suite 510, Fort Lee, NJ, USA; Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.
Siu C; COS & Associates Ltd., 20/F Central Tower, 28 Queen's Rd, Central District, Hong Kong.
Tsai J; Sunovion Pharmaceuticals Inc., 1 Bridge Plaza North, Suite 510, Fort Lee, NJ, USA; Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.
Koblan K; Sunovion Pharmaceuticals Inc., 1 Bridge Plaza North, Suite 510, Fort Lee, NJ, USA; Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.
Loebel A; Sunovion Pharmaceuticals Inc., 1 Bridge Plaza North, Suite 510, Fort Lee, NJ, USA; Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.
Pokaż więcej
Źródło :
Brain, behavior, and immunity [Brain Behav Immun] 2018 Oct; Vol. 73, pp. 717-724. Date of Electronic Publication: 2018 Aug 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Bipolar Disorder/*drug therapy
C-Reactive Protein/*metabolism
Lurasidone Hydrochloride/*pharmacology
Adult ; Antidepressive Agents/therapeutic use ; Antimanic Agents/therapeutic use ; Biomarkers, Pharmacological/blood ; Biomarkers, Pharmacological/metabolism ; Bipolar Disorder/physiopathology ; C-Reactive Protein/analysis ; C-Reactive Protein/physiology ; Depressive Disorder, Major/drug therapy ; Double-Blind Method ; Female ; Humans ; Lurasidone Hydrochloride/metabolism ; Male ; Middle Aged ; Outpatients ; Psychiatric Status Rating Scales ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.
Autorzy :
Greenblatt DJ
Harmatz JS
Ryan MJ; Emerald Lake Safety, Newport Beach, CA.
Chow CR; Emerald Lake Safety, Newport Beach, CA.
Pokaż więcej
Źródło :
Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2018 Aug; Vol. 38 (4), pp. 289-295.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Antifungal Agents/*pharmacology
Antipsychotic Agents/*pharmacokinetics
Cytochrome P-450 CYP3A Inhibitors/*pharmacology
Lurasidone Hydrochloride/*pharmacokinetics
Obesity/*metabolism
Triazoles/*pharmacology
Adult ; Antifungal Agents/administration & dosage ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/blood ; Body Mass Index ; Cytochrome P-450 CYP3A Inhibitors/administration & dosage ; Drug Administration Schedule ; Drug Interactions ; Female ; Humans ; Lurasidone Hydrochloride/administration & dosage ; Lurasidone Hydrochloride/blood ; Male ; Triazoles/administration & dosage
Czasopismo naukowe
Tytuł :
Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride.
Autorzy :
Heng W
Su M
Cheng H
Shen P
Liang S
Zhang L; Department of Chemistry , Smith College , Northampton , Massachusetts 01063 , United States.
Wei Y
Gao Y
Zhang J
Qian S
Pokaż więcej
Źródło :
Molecular pharmaceutics [Mol Pharm] 2020 Jan 06; Vol. 17 (1), pp. 84-97. Date of Electronic Publication: 2019 Dec 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antipsychotic Agents/*chemistry
Lurasidone Hydrochloride/*chemistry
Biological Availability ; Calorimetry, Differential Scanning ; Chemistry, Pharmaceutical ; Crystallization ; Cysteine/chemistry ; Drug Stability ; Hydrogen Bonding ; Hydrogen-Ion Concentration ; Magnetic Resonance Spectroscopy ; Solubility ; Spectroscopy, Fourier Transform Infrared ; Spectrum Analysis, Raman ; X-Ray Diffraction
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies